Description:
Kadcyla (ado-trastuzumab emtansine) is a targeted therapy used in the treatment of HER2-positive breast cancer that has spread to other parts of the body or cannot be surgically removed. It combines the targeting ability of trastuzumab (Herceptin) with a chemotherapy drug (emtansine) to specifically deliver chemotherapy to cancer cells, minimizing damage to healthy cells.
Ingredients:
- Active Ingredient: Ado-trastuzumab emtansine 160 mg (equivalent to 100 mg trastuzumab and 3.6 mg DM1 [emtansine]).
- Inactive Ingredients: Not applicable for infusions.
Usage Instructions:
- Kadcyla is administered by a healthcare professional as an intravenous (IV) infusion.
- The recommended dosage is based on body weight and other medical conditions.
- It is usually given once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity occurs.
- Pre-medication may be given to reduce the risk of infusion-related reactions.
- Blood tests and cardiac monitoring may be required before and during treatment to monitor for potential side effects.
Benefits:
- Targeted therapy for HER2-positive breast cancer.
- Delivers chemotherapy directly to cancer cells, reducing systemic side effects.
- Helps to control cancer growth and improve overall survival rates.
- Administered every 3 weeks, offering convenience for patients.
Precautions:
- For use under the supervision of a qualified healthcare professional experienced in the use of cancer therapies.
- Not suitable for patients with known hypersensitivity to trastuzumab or emtansine.
- Potential side effects include infusion reactions, cardiac toxicity, liver problems, and decreased blood cell counts.
- Pregnancy category D: Can cause fetal harm; use effective contraception during treatment and for several months after stopping.
- Monitor closely for signs of heart problems and liver toxicity.
Storage Instructions:
- Store Kadcyla vials in the refrigerator at 2-8°C (36-46°F).
- Protect from light.
- Do not freeze.
- Keep out of reach of children and pets.Roche
- Use within 24 hours after preparation if stored at room temperature (15-30°C / 59-86°F) or within 24 hours after refrigeration if stored in the refrigerator.
Manufacturer:
Roche Holding AG Pharmaceutical company
